Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model
Christina L. Hutson, Ashley V. Kondas, Matthew R. Mauldin, Jeffrey B. Doty, Irma M. Grossi, Clint N. Morgan, Sharon Dietz Ostergaard, Christine M. Hughes, Yoshinori Nakazawa, C. Kling, Brock E. Martin, James A. Ellison, Darin D. Carroll, Nadia Gallardo‐Romero, Victoria A. Olson
Abstract
Preparedness activities against highly transmissible viruses with high mortality rates have been highlighted during the ongoing coronavirus disease 2019 (COVID-19) pandemic. Smallpox, caused by variola virus (VARV) infection, is highly transmissible, with an estimated 30% mortality.
Topics & Concepts
MonkeypoxVariola virusSmallpoxVirologyPharmacokineticsMedicineCmaxVirusPharmacologyVacciniaBiologyVaccinationBiochemistryRecombinant DNAGenePoxvirus research and outbreaksHerpesvirus Infections and TreatmentsBacillus and Francisella bacterial research